⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15647806 | 0.62 | — | — | |
| SCHEMBL9472108 | 0.57 | — | — | |
| SCHEMBL2163069 | 0.57 | — | — | |
| SCHEMBL845389 | 0.57 | — | — | |
| SCHEMBL502054 | 0.57 | — | — | |
| SCHEMBL14861274 | 0.55 | — | — | |
| SCHEMBL15541274 | 0.55 | — | — | |
| SCHEMBL2558345 | 0.55 | — | — | |
| SCHEMBL7902873 | 0.53 | — | — | |
| SCHEMBL3300453 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. | 2023-05-02 | — | — | US | disclosed |
| US-10981905-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-04-20 | — | — | US | disclosed |
| US-20200354354-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-11-12 | — | — | US | disclosed |
| US-10815229-B1 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-10-27 | — | — | US | disclosed |
| US-10662184-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-05-26 | — | — | US | disclosed |
| US-20200157089-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-05-21 | — | — | US | disclosed |
| CN-110121347-A | The method for preparing sulfonylureas bile acid derivative | 英安塔制药有限公司 | 2019-08-13 | — | — | CN | disclosed |
| US-20190194184-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2019-06-27 | — | — | US | disclosed |
| US-10246453-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2019-04-02 | — | — | US | disclosed |
| EP-3458449-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2019-03-27 | — | — | EP | disclosed |
| CN-103073488-A | Synthesis method of sulfonamide formate | ANHUI JUKAI AGRICULTURAL CO LTD | 2013-05-01 | — | — | CN | disclosed |
| WO-2012174312-A2 | BENZIMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-12-20 | — | — | WO | disclosed |
| CN-1140268-C | Rapamycin formulations for oral administration | — | 2004-03-03 | — | — | CN | disclosed |
| CN-1108152-C | Rapamycin formulations for oral administration | WYETH CORP (US) | 2003-05-14 | — | — | CN | disclosed |
| CN-1107500-C | Rapamycin formulations for oral administration | WYETH CORP (US) | 2003-05-07 | — | — | CN | disclosed |
| CN-1214039-A | Carbamoyloxy derivatives of mutiline and their use as antibacterials | SMITHKLINE BEECHAM PLC (GB) | 1999-04-14 | — | — | CN | disclosed |
| CN-1197639-A | Rapamycin formulations for oral administration | AMERICAN HOME PROD (US) | 1998-11-04 | — | — | CN | disclosed |
| CN-1109746-A | Rapamycin formulations for oral administration | AMERICAN HOME PROD (US) | 1995-10-11 | — | — | CN | disclosed |
| CN-1108931-A | Rapamycin formulations for oral administration | AMERICAN HOME PROD (US) | 1995-09-27 | — | — | CN | disclosed |
| CN-1108529-A | Rapamycin formulations for oral administration | AMERICAN HOME PROD (US) | 1995-09-20 | — | — | CN | disclosed |